Related Experiment Video
Updated: Sep 20, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.8K
siRNA-based therapeutics for lipoprotein (a) lowering: A path toward precision cardiovascular medicine
Mehmet Kanbay1, Lasin Ozbek2, Mustafa Guldan2
1Department of Medicine, Section of Nephrology, Koc University School of Medicine, Istanbul, Turkey.
European Journal of Clinical Investigation
|May 23, 2025
Summary
Elevated lipoprotein(a) [Lp(a)] is a key cardiovascular risk factor. Small interfering RNA (siRNA) therapies effectively lower Lp(a), showing promise for improving cardiovascular outcomes.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Pharmacology
Background:
- Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular diseases.
- Lp(a) possesses pro-inflammatory and pro-thrombotic properties, contributing to cardiovascular disease pathogenesis.
- Current Lp(a)-lowering interventions' contribution to cardiovascular benefits is not fully understood.
Purpose of the Study:
- To review the pathophysiological role of Lp(a) in cardiovascular disease.
- To analyze siRNA-based therapeutics targeting Lp(a), including mechanisms, efficacy, and safety.
- To discuss other RNA-based approaches and future perspectives in Lp(a) modulation.
Main Methods:
- Comprehensive literature review of Lp(a) pathophysiology and therapeutic strategies.
- Analysis of clinical trial data on siRNA efficacy and safety for Lp(a) reduction.
- Examination of potential risks, limitations, and challenges of Lp(a)-targeting treatments.
Main Results:
- siRNA therapies demonstrate significant efficacy in lowering Lp(a) levels.
- Ongoing research investigates the impact of Lp(a) reduction on cardiovascular outcomes.
- Various RNA-based approaches are being explored for Lp(a) modulation.
Conclusions:
- Targeting Lp(a) represents a significant therapeutic strategy for cardiovascular disease prevention.
- siRNA therapies offer a promising approach for Lp(a) reduction.
- Further research and clinical trials are essential to establish the full potential of Lp(a)-modulating treatments.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
900
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
900
01:26Atherosclerosis III: Management
44
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
44
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
01:26Coronary Artery Disease IV: Preventive Measures
41
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
41
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
303
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
303
01:27Coronary Artery Disease V: Interprofessional Care
40
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
40